Enalapril maleate salt
SIGMA/E6888 - powder, ≥98% (TLC)
Synonym: (S)
CAS Number: 76095-16-4
Empirical Formula (Hill Notation): C20H28N2O5 · C4H4O4
Molecular Weight: 492.52
EC Number: 278-375-7
Linear Formula: C20H28N2O5 · C4H4O4
Product Type: Chemical
| assay | ≥98% (TLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C21H30N2O5.C4H4O5/c1-3 |
| InChI key | UQKQUZOIQFOJOI-KJHLASMFSA |
| originator | Merck & Co., Inc., Kenilworth, NJ, U.S. |
| Quality Level | 100 ![]() |
| SMILES string | C[C@@H](C(N1[C@H](C(O)=O) |
| solubility | methanol: ≥50 mg/mL, clear, colorless to yellow |
| Application: | Enalapril maleate salt has been used: • to reduce albumin excretion rate (AER) and glomerular lesions • to examine the effects of enalapril pre-treatment on myocardial injury • to investigate its efficacious doses and schedules for mitigation of radiation lung injury |
| Biochem/physiol Actions: | A long-acting angiotensin-converting enzyme inhibitor. |
| Features and Benefits: | This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: | This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Enalapril is an angiotensin-converting enzyme inhibitor. It is used to treat heart failure and high blood pressure. |
| Packaging: | 1, 5 g in poly bottle |
| Packaging: | 250 mg in poly bottle |
| Symbol | GHS08 |
| Signal word | Warning |
| Hazard statements | H361fd |
| Precautionary statements | P201 - P202 - P280 - P308 + P313 - P405 - P501 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Purity | ≥98% (TLC) |
| UNSPSC | 12352200 |


